Drugs / Fludarabin
Trials 0
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06649227 Background | Jul 2025 → Jul 2029 expected | acute myeloid leukemia | University Hospital, Lille | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05296564 Background | Apr 2022 → Dec 2027 expected | metastatic malignant neoplasm, metastatic melanoma, neuroblastoma, non-small cell lung carcinoma +4 | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01786018 Background | Feb 2013 → Feb 2015 | aggressive B-cell non-Hodgkin lymphoma | Azienda Ospedaliera San Giovanni Battista | Unknown | No outcome recorded |
| Phase 2 | NCT01849939 Background | Sep 2012 → Sep 2017 | B-cell chronic lymphocytic leukemia | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04000698 Background | Oct 2019 → Jul 2022 | acute lymphoblastic leukemia, acute myeloid leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludarabin | “cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.” NCT06649227 ↗4“Preparative chemotherapy before allogeneic HSCT * Fludarabin” NCT04000698 ↗ |